knowledge -WSS

knowledge

author：leisure time 2025-10-03 00:40:13 - browse：214

Senate Health, Education, Labor, and Pensions Chair Sen. Bernie Sanders, I-Vt., points toward a poster detailing what he said the U.S. versus the "Rest of the World" spends on prescription drugs, during a hearing to examine the cost of prescription drugs. -- health policy coverage — Sen. Bernie Sanders (I-Vt.) raises his hand at a Thursday hearing on Capitol Hill in Washington to examine the cost of prescription drugs. Jacquelyn Martin/AP

WASHINGTON — Call it Sen. Bernie Sanders’ prescription drug pricing theater.

The hearing, featuring Merck CEO Robert Davis, Johnson & Johnson CEO Joaquin Duato, and Bristol Myers Squibb CEO Chris Boerner, was designed to draw public interest, and in that respect, it worked. The wood-paneled hearing room in a Senate office building was standing room only, with an overflow room prepared. Photographers flocked for photos as Sanders shook hands with each executive, standard practice before such hearings begin.

Sanders’ staff got an arm workout switching out foam boards behind the chairman’s head, illustrating how the drug companies called to testify make more revenue from the United States on certain medications than the rest of the world combined.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Popular nasal decongestant doesn't actually relieve congestion

focus

WSS

Spinal cord stimulation reduces pain in amputees, study finds

Pfizer plans to depart BIO

Chemotherapy shortages won’t get better under Biden’s latest plan

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Food makers tried to stack nutrition panel with preferred experts

PEPFAR is under serious threat — and so is global health

Wikipedia

knowledge

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Walmart eyes Medicare Advantage provider ChenMed

George Santos makes 1st court appearance after pleading not guilty to 13 counts

How to make the FDA’s new prescription one

Duchenne breakthrough therapy leaves behind pioneering families

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Cancer drug shortages should be causing more outrage

Roche to buy Carmot Therapeutics, developer of obesity drugs

Duchenne breakthrough therapy leaves behind pioneering families

PEPFAR is under serious threat — and so is global health

focus

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Popular nasal decongestant doesn't actually relieve congestion

Food makers tried to stack nutrition panel with preferred experts

After sickle

focus

focus

entertainment

focus